Biotech’s Broken Math | Ep. 994

Is China the Fix?

Hello Avatar! Welcome back for another week of biotech analysis. Today is Sunday, which means this is our Building Biotech newsletter that is focused on discussing biopharma strategy topics. This week, we dig into the hard math behind biotech’s broken business model, and why capital efficiency, not just scientific novelty, will define the next generatio…